Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 833

1.

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Millan MJ.

Neurotherapeutics. 2009 Jan;6(1):53-77. doi: 10.1016/j.nurt.2008.10.039. Review.

PMID:
19110199
2.

[Efficacy of atypical antipsychotics in depressive syndromes].

Quintin P, Thomas P.

Encephale. 2004 Nov-Dec;30(6):583-9. Review. French.

PMID:
15738862
3.

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.

Kasper S, Hamon M.

World J Biol Psychiatry. 2009;10(2):117-26. doi: 10.1080/15622970902717024. Review.

PMID:
19255935
5.

[Fluoxetine: an update of its use in major depressive disorder in adults].

Gourion D, Perrin E, Quintin P.

Encephale. 2004 Jul-Aug;30(4):392-9. Review. French.

PMID:
15597466
6.

[Mechanism of action of antidepressants and therapeutic perspectives].

Bourin M, David DJ, Jolliet P, Gardier A.

Therapie. 2002 Jul-Aug;57(4):385-96. Review. French.

PMID:
12422559
8.

Monoamine neurocircuitry in depression and strategies for new treatments.

Hamon M, Blier P.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:54-63. doi: 10.1016/j.pnpbp.2013.04.009. Epub 2013 Apr 19. Review.

PMID:
23602950
9.

The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.

Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Poeggeler B, Hardeland R, Cardinali DP.

World J Biol Psychiatry. 2009;10(4 Pt 2):342-54. doi: 10.1080/15622970701625600. Review.

PMID:
18609422
10.

Duloxetine pharmacology: profile of a dual monoamine modulator.

Karpa KD, Cavanaugh JE, Lakoski JM.

CNS Drug Rev. 2002 Winter;8(4):361-76. Review.

11.

Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?

Adell A.

Curr Drug Targets CNS Neurol Disord. 2004 Apr;3(2):113-21. Review. Erratum in: Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3)269.

PMID:
15078186
13.

Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders.

Ogren SO, Kuteeva E, Hökfelt T, Kehr J.

CNS Drugs. 2006;20(8):633-54. Review.

PMID:
16863269
14.

Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors.

Guiard BP, El Mansari M, Blier P.

Curr Drug Targets. 2009 Nov;10(11):1069-84. Review.

PMID:
19702555
15.

Treating each and every depressed patient.

Kennedy SH.

J Psychopharmacol. 2008 Sep;22(7 Suppl):19-23. doi: 10.1177/0269881108093270. Review.

PMID:
18753279
16.

Triple uptake inhibitors: therapeutic potential in depression and beyond.

Chen Z, Skolnick P.

Expert Opin Investig Drugs. 2007 Sep;16(9):1365-77. Review.

PMID:
17714023
17.
19.

Novel serotonergic mechanisms and clinical experience with nefazodone.

Fontaine R.

Clin Neuropharmacol. 1993;16 Suppl 3:S45-50. Review.

PMID:
8131154
20.

Emerging drugs for major depressive disorder.

Kennedy SH, Rizvi SJ.

Expert Opin Emerg Drugs. 2009 Sep;14(3):439-53. doi: 10.1517/14728210903107751. Review.

PMID:
19637989
Items per page

Supplemental Content

Write to the Help Desk